Mounjaro 5mg side effects: what the evidence shows

What the SURMOUNT trial data tells us about side effects at this stage

The SURMOUNT clinical programme, which enrolled thousands of adults with obesity across its phases, captured side-effect data across all doses including the early titration period when 5mg is typically active. Published in the New England Journal of Medicine, SURMOUNT-1 showed that gastrointestinal reactions were the predominant class of events across the active arms, with the highest incidence concentrated in the dose-escalation phase rather than at steady maintenance.

At 5mg specifically, most participants were in their second month of treatment, past the initial adjustment but not yet at a higher maintenance level. Nausea was reported by a meaningful proportion of participants, but rates of discontinuation due to side effects remained low relative to the placebo comparison. The practical reading of this: 5mg is a transition dose, and the GI symptoms many people notice are a recognisable physiological response to slowed gastric emptying rather than a sign of harm.

Fatigue, headache and dizziness also appeared in the trial data at rates above placebo during titration, and injection-site reactions such as redness or mild swelling at the abdomen, thigh or upper arm were occasionally noted. These are worth knowing about, even if they affect a minority. For a broader look at how Mounjaro works at a clinical level, our Mounjaro overview sets out the dual GIP and GLP-1 mechanism behind both its effects and its tolerability profile.

The specific effects people notice when stepping up from 2.5mg to 5mg

A question our prescribers hear most weeks is whether the side effects get worse when the dose goes up. The short answer: sometimes yes, briefly. Moving from 2.5mg to 5mg can trigger a second, milder wave of nausea or loose stools as the body adjusts to the higher level of receptor activation. Most people find this settles within one to two weeks.

The transition from 2.5mg to 5mg matters because the timing and pattern of any new symptoms can tell you a lot. Nausea that arrives in the day or two after the injection and then fades is typical. Nausea that is constant, severe or accompanied by significant vomiting is not typical and warrants a call to your prescriber or GP. Eating smaller portions, choosing lower-fat meals and staying well hydrated all have good evidence behind them for reducing GI discomfort during titration.

Constipation is worth flagging separately. It is less discussed than nausea but can be more persistent, partly because Mounjaro slows gut motility. Adequate fibre and fluid intake help; if constipation becomes problematic, speak to your prescriber before reaching for laxatives, as some interact with other medicines. If you want to understand what people typically experience before reaching this dose, our page covering the side effects of Mounjaro 2.5mg gives useful context on the starting point most patients come from. Details on how dosing schedules are managed across the full course sit on our page about how often the maintenance dose is taken.

When to get medical help, and what the MHRA flags as urgent

The vast majority of side effects at 5mg are uncomfortable rather than dangerous. The distinction matters, and the MHRA has been clear about where the threshold for urgent attention lies.

In its January 2026 Drug Safety Update on GLP-1 receptor agonists, the MHRA highlighted acute pancreatitis as an infrequent but serious risk. The warning sign is severe abdominal pain (often described as radiating through to the back) that does not ease and may come with vomiting. If that describes what you are experiencing, stop the injection and get urgent medical help; do not wait for your next prescriber review. You can find the full MHRA Drug Safety Update guidance on GOV.UK.

Other situations that need prompt attention rather than watchful waiting: signs of a severe allergic reaction (swelling of the face or throat, difficulty breathing), symptoms of significant dehydration from persistent vomiting or diarrhoea (dark urine, dizziness on standing, very little urine output), or any sudden change in mood or thoughts of self-harm. Gallbladder symptoms (sharp pain in the upper right abdomen, sometimes with fever) have also been reported with GLP-1 medicines and should be assessed by a doctor. If you have questions specific to your situation, our team is available seven days a week.

For context on what side effects look like at higher doses as treatment progresses, our page on 10mg Mounjaro side effects covers what changes and what typically stays the same when patients reach that stage, and the page on Mounjaro 7.5mg side effects covers what changes and what typically stays the same at the intermediate step.

Reporting side effects and the role of ongoing clinical oversight

Reporting suspected side effects matters, and the UK has a straightforward route for it. Any patient on Mounjaro can submit a Yellow Card report at yellowcard.mhra.gov.uk, this includes reactions that feel minor, because aggregate data from real-world use genuinely informs post-market safety monitoring. The MHRA's Black Triangle (▼) designation for Mounjaro means it is subject to additional scrutiny, and patient reports are part of that.

Clinical oversight does not stop at the prescription. At nume, a GPhC-registered prescriber reviews the position before every repeat, checking how the current dose is being tolerated and whether progression is appropriate. That review matters most at the 5mg stage, when people are still finding their rhythm. If you want to understand whether treatment is likely to suit you before starting, checking your eligibility through a free consultation is the right first step. Our prescribers discuss the side-effect profile, your health history and any medicines you already take before anything is prescribed. There is no obligation and no algorithm deciding the answer.